PMA supplement
P160031 S004: ASPIRE Cristalle Digital Breast Tomosynthesis (DBT) Option
FDA PMA supplement · Real-Time Process · Fujifilm Medical Systems U.S.A, Inc.
Key facts
| Original PMA | P160031 |
|---|---|
| Supplement number | S004 |
| Supplement type | Real-Time Process |
| Reason for the supplement | Change Design/Components/Specifications/Material |
| Trade name | ASPIRE Cristalle Digital Breast Tomosynthesis (DBT) Option |
| Generic name | Digital breast tomosynthesis |
| Applicant | Fujifilm Medical Systems U.S.A, Inc. |
| Product code | OTE |
| Received date | Nov 15, 2022 |
| Decision date | Feb 13, 2023 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: